The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of ...

KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients ...

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

The phase 3 KEYNOTE‑B96 trial showed that Keytruda plus paclitaxel, with or without Avastin, improved overall survival in patients with platinum‑resistant ovarian cancer. From your perspective, what ...

Merck presents positive results from phase 3 LITESPARK-022 trial of Keytruda plus Welireg in certain patients with earlier-stage RCC at 2026 ASCO cancers symposium: Rahway, New Je ...

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...